Last reviewed · How we verify
HR091506 tablet
At a glance
| Generic name | HR091506 tablet |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults (PHASE3)
- A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy Subjects (PHASE1)
- Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults (PHASE3)
- A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HR091506 tablet CI brief — competitive landscape report
- HR091506 tablet updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI